Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-07-04
2006-07-04
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C530S325000, C530S326000, C530S327000, C530S328000
Reexamination Certificate
active
07070780
ABSTRACT:
Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of an ordered peptide comprising a repeated motif {SEQ ID NO: 1} [1E2Y3Y4K]n, where n is from 2 to 6. Some specific peptides of interest include those having the sequence {SEQ ID NO:4} EYYKEYYKEYYK. The peptide may consist only of the ordered repeats, or may be extended at either termini by the addition of other amino acid residues. For therapy, the peptides may be administered topically or parenterally, e.g. by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. In a preferred embodiment, subcutaneous injection is used to deliver the peptide. The subject methods are used for prophylactic or therapeutic purposes. The compositions of the invention may also contain other therapeutically active agents, e.g. immunosuppressants, β-interferon, steroids, etc.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853914 (1974-12-01), Goldstein et al.
patent: 3905654 (1975-09-01), Tribe
patent: 4043989 (1977-08-01), Schneider et al.
patent: 4069105 (1978-01-01), Singh
patent: 4156081 (1979-05-01), Singh et al.
patent: 6531130 (2003-03-01), Steinman et al.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Van Noort et al, International Reivew of Cytology 178: 127-205, 1998.
Ngo et al, 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Aharoni et al. (Sep. 1997), “Copolymer 1 Induces T Cells of the T Helper Type 2 that Crossreact with Myelin Basic Protein and Suppress Experimental Autoimmune Encephalomyelitis.”Proc. Natl. Acad. Sci. USA,vol. 94:10821-10826.
Fridkis-Hareli et al. (1999), “Bonding Motifs of Copolymer 1 to Multiple Sclerosis and Rheumatoid Arthritis-Associated HLA-DR Molecules.”Journal of Immunology,vol. 162:4697-4704.
Hafler et al. (1997), “Oral Administration of Myelin Induces Antigen-Specific TGF-β1 Secreting T Cells in Patients with Multiple Sclerosis,”Ann. NY Acad. Sci., vol. 835:120-131.
Karin et al. (Dec. 1994), “Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Based Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon γ and Tumor Necrosis Factor α Production.”J. Exp. Med.,vol. 180:2227-2237.
Kennedy et al. (1997), “Induction of Antigen-Specific Tolerance for the Treatment of Ongoing, Relapsing Autoimmune Encephalomyelitis.”Journal of Immunology,vol. 159:1036-1044.
Maru{hacek over (s)}ić et al. (Aug. 18, 1997), “Tolerance Induction and Autoimmune Encephalomyelitis Amelioration After Administration of Myelin Basic Protein-Derived Peptide.”J. Exp. Med.,vol. 186(4):507-515.
Merrifield, R.B. (Jul. 20, 1963), “Solid Phase Peptide Synthesis.”J. Am. Chem. Soc.,vol. 85:2149-2154.
Miller et al. (1998), “Treatment of Multiple Sclerosis with Copolymer-1 (Copaxone ®): Implicating Mechanisms of Th1 to Th2/Th3 Immune-Deviation.”Journal of Neuroimmunology,vol. 92:113-121.
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 491-495.
Reiseter et al. (1998), “Treatment of Murine Experimental Autoimmune Encephalomyelitis with a Myelin Based Protein Peptide Analog Alters the Cellular Composition of Leukocytes Infiltrating the Cerebrospinal Fluid.”Journal of Neuroimmunology,vol. 91:156-170.
Sakai et al. (Dec. 1989), “Prevention of Experimental Encephalomyelitis with Peptides that Block Interaction of T Cells with Major Histocompatibility Complex Proteins.”Proc. Natl. Acad. Sci. USA,vol. 86:9470-9474.
Steinman et al. (1995), “Major T-Cell Responses in Multiple Sclerosis.”Mol. Med. Today,vol. 1:79-83.
Steinman, Lawrence (Jun. 29, 1995), “Presenting an Odd Antigen.”Nature,vol. 375:739-740.
Steinman, Lawrence (Jan. 13, 1977), “Regulation of Autosensitization to Encephalitogenic Myelin Basic Protein by Macrophage-Associated and Soluble Antigen.”Nature,vol. 265:173-175.
Warren et al. (Nov. 1995), “Fine Specificity of the Antibody Response to Myelin Basic Protein in the Central Nervous System in Multiple Sclerosis: The Minimal B-Cell Epitope and a Model of its Features.”Proc. Natl. Acad. Sci. USA,vol. 92:11061-11065.
Wraith et al. (Oct. 20, 1989), “Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy.”Cell,vol. 59:247-255.
Ruiz Pedro José
Steinman Lawrence
Board of Trustees of the Leland Stanford Junior University
Chan Christina
Huynh Phuong
Townsend & Townsend & Crew
LandOfFree
Treatment of demyelinating autoimmune disease with ordered... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of demyelinating autoimmune disease with ordered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of demyelinating autoimmune disease with ordered... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3602094